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Hepatocellular carcinoma (HCC) is one of the most
common cancers worldwide, often diagnosed at an
advanced stage when the most potentially curative stra-
tegies are no longer effective. Advances in the under-
standing of tumor biology are opening new paths for
the prevention and treatment of HCC, through the
development of new targeted therapies. The design of
drugs that block different growth-promoting pathways,
activate apoptotic pathways may also open new horizons
in the treatment of HCC.
The aim of this study was to test the efficacy of new
targeted drugs involved in signalling pathways, such as
farnesiltransferase (L-744832) and mTOR inhibitors
(everolimus) in a HCC cell line (HUH-7 cells).
The HUH-7 cells were cultured in absence and pre-
sence of diferent concentrations of L-744832 and evero-
limus. The antiproliferative effect was assessed by the
Alamar Blue assay and cell death by optic microscopy
and flow cytometry.
Our results showed that farnesiltransferase and mTOR
inhibitors had an antiproliferative and cytotoxic effects
in monotherapy in a dose and time dependent manner,
inducing cell death preferentially by apoptosis. On, the
other hand, the combination of L-744832 and everoli-
mus with conventional anticarcinogenic drugs demon-
strated a higher antiproliferative and cytotoxic effect for
lower doses than the IC50 used in monotherapy (addi-
tion or potentiation synergism).
These results suggested that farnesiltransferase and
mTOR inhibitors may constitute a new potential
therapeutic approach in HCC either in monotherapy or
in association with conventional therapies.
Author details
1Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal.
2Center of Investigation on Environment, Genetics and Oncobiology
(CIMAGO), FMUC, Coimbra, Portugal.
3Medicine Service and Hepatology Unit,
University Hospital of Coimbra, Coimbra, Portugal.
Published: 24 September 2010
doi:
Cite this article as: Araújo et al.: Antitumoral effect of farnesiltransferase
and mtor inhibitors in hepatocellular carcinoma: in vitro studies. BMC
Proceedings 2010 4(Suppl 2):P49.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: anamfa@gmail.com
1Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal
Full list of author information is available at the end of the article
Araújo et al. BMC Proceedings 2010, 4(Suppl 2):P49
http://www.biomedcentral.com/1753-6561/4/S2/P49
© 2010 Araújo et al; licensee BioMed Central Ltd.